NON-SMALL CELL LUNG CARCINOMA

This early-phase trial is testing whether combining two drugs—retifanlimab and ruxolitinib—can safely help people with advanced lung or kidney cancer whose disease has progressed after prior immunotherapy. About 40 participants will take ruxolitinib pills twice daily and receive …

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose and see if the combinatio…

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. About 60 adults with operable stage IB-IIIA NSCLC will receive …

This study is tracking how safe and effective the drug Tabrecta (Capmatinib) is for people with a specific type of lung cancer (non-small-cell lung cancer with an exon 14 skipping mutation). About 44 participants in South Korea will receive the drug as part of their normal care, …

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …

This observational study is following 100 adults with metastatic non-small cell lung cancer who have certain EGFR mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers want to see how long the treatment keeps the can…